Acs Fall 2024 Vvd-130037 Vvd1300375. Vividion has already disclosed work on covalent keap1 inhibitors, but at the recent acs fall 2024 meeting, the structure and discovery story of their clinical oral covalent activator of. Explore acs fall 2024 agenda:
Vividion has already disclosed work on covalent keap1 inhibitors, but at the recent acs fall 2024 meeting, the structure and discovery story of their clinical oral covalent. Technical sessions, networking, career development & more.
Acs Fall 2024 Vvd-130037 Vvd1300375 Images References :